Stamford, CT -- (SBWIRE) -- 12/06/2013 -- Wall Street Pennies is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: American Capital Agency Corp.(NASDAQ:AGNC), Generex Biotechnology Corporation(OTCMKTS:GNBT), Array Biopharma Inc(NASDAQ:ARRY), Boston Scientific Corporation(NYSE:BSX)
American Capital Agency Corp.(NASDAQ:AGNC) managed to keep its fall at -1.47% on above-normal volume of 8.84 million shares. The stock settled at $19.46 after floating in a range of $19.26 to $19.66. Its latest price was $19.46, reaching market capitalization of $7.48 billion. Its 52-week range has been $19.21 to $33.31. American Capital Agency Corp. (AGNC) is a real estate investment trust (REIT). The Company earns income primarily from investing on a leveraged basis in agency mortgage-backed securities. These investments consist of residential mortgage pass-through securities and collateralized mortgage obligations (CMOs) for which the principal and interest payments are guaranteed by government-sponsored entities.
Has AGNC Found The Bottom and Ready To Move Up? Find Out Here
Generex Biotechnology Corporation(OTCMKTS:GNBT) traded down on a volume of 2.63 million, higher than its standard daily volume. Shares have dropped -1.94% to $0.0304. Over the last twelve months, the stock has lost -22.54% and faced a worst price of $0.02. Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity.
Has GNBT Found The Bottom And Ready To Gain Momentum? Find Out Here
Array Biopharma Inc(NASDAQ:ARRY) settled -1.65% lower at $5.96 on below-normal volume of 1.39 million shares during the last trading day. The stock has its 12-month high at $7.10 and 52-week low price was $3.41. It traded in a range of $5.86 to $6.05 during the last trading day. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways.
Why Should Investors Buy ARRY After the Recent Fall ? Just Go Here and Find Out
Boston Scientific Corporation(NYSE:BSX) saw its price gain on below-normal volume, as 8.94 million shares changed hands when compared with its average daily volume of 12.73 million shares. The stock was up 0.27% to $11.34. It has gained over the last 12 months, increasing 104.94% and marked new low $5.46. Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women’s Health, Neuromodulation, and Electrophysiology.
Why Should Investors Buy BSX After The Recent Gain? Just Go Here and Find Out
About Wall Street Pennies
Wall Street Pennies is always penetrating the market every day for enormous penny stock runs before they happen in order to assist its customers. Our Penny Stock Newsletter also offers free market strategies and analysis from one of the most experienced and well-respected chartists in the penny stock industry.
Carriage Consulting Group, http://www.wallstreetpennies.com,, their Members, officers, directors, employees, affiliates, or any other related person(s) (collectively, “www.wallstreetpennies.com,”) are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. Wall Street Pennies as defined are neither licensed nor qualified to provide investment advice and you are specifically and adamantly advised not to rely upon anything said/posted/communicated/implied or expressed by www.wallstreetpennies.com, as defined.
Read full Disclaimer at: http://wallstreetpennies.com/financial-disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)